Author:
Ishikawa Akira,Fukui Takafumi,Kido Aya,Katsuya Narutaka,Kuraoka Kazuya,Uraoka Naohiro,Suzuki Takahisa,Oka Shiro,Kotachi Takahiro,Ashktorab Hassan,Smoot Duane,Yasui Wataru
Abstract
ABSTRACTBackgroundGastric cancer (GC) is characterized by significant intratumoral heterogeneity and stem cells presenting as promising therapeutic targets. Despite advancements in spatial transcriptome analysis, unexplored targets for addressing cancer stemness remain unknown. This study aims to identify Nuclear Factor IX (NFIX) as a critical regulator of cancer stemness in GC and evaluate its clinicopathological significance and function.MethodsSpatial transcriptome analysis was conducted on GC. NFIX expression’s correlation with clinicopathological factors and prognosis was assessed through immunostaining in 127 GC cases. Functional analyses in cancer cell lines validated these findings.ResultsSpatial transcriptome analysis stratified GC tissues based on genetic profiles, pinpointing CSC-like cells and further refined the classification to identify and highlight the NFIX’s significance, validated by Monocle 3 and CytoTRACE analyses. Knockdown experiments in cancer cell lines demonstrated the involvement of NFIX in cancer cell proliferation and kinase activity.ConclusionsThis study underscores spatial transcriptome analysis’s role in refining GC tissue classification and identifying therapeutic targets, highlighting NFIX as pivotal. NFIX expression correlates with poor prognosis and drives GC progression, suggesting its potential as a novel therapeutic target for personalized GC therapies.
Publisher
Cold Spring Harbor Laboratory